Enanta Pharmaceuticals Inc Cash Flow Conversion Efficiency
Enanta Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) has a cash flow conversion efficiency ratio of -0.099x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.97 Million) by net assets ($101.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Enanta Pharmaceuticals Inc (2011–2025)
Cash flow conversion efficiency of Enanta Pharmaceuticals Inc from 2011 to 2025. This chart illustrates how Enanta Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Enanta Pharmaceuticals Inc share price for real-time trading data and today's change.
Enanta Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Enanta Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Enanta Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enanta Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Enanta Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Divgi Torqtransfer Systems Limited
NSE:DIVGIITTS
|
0.016x |
|
HLE Glascoat Limited
NSE:HLEGLAS
|
0.121x |
|
Bourrelier Group SA
PA:ALBOU
|
0.072x |
|
BK Technologies Inc
NYSE MKT:BKTI
|
0.067x |
|
Halk Gayrimenkul Yatirim Ortakligi AS
IS:HLGYO
|
-0.056x |
|
Suzhou Fushilai Pharmaceutical Co. Ltd.
SHE:301258
|
N/A |
|
Biofarm Bucure
RO:BIO
|
0.052x |
|
Guangdong Real-Design Intelligent Technology Co. Ltd.
SHE:301135
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Enanta Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Enanta Pharmaceuticals Inc from 2011 to 2025. Review how much free cash does Enanta Pharmaceuticals Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $64.72 Million | $-19.27 Million | -0.298x | +51.30% |
| 2024-09-30 | $128.81 Million | $-78.76 Million | -0.611x | -28.47% |
| 2023-09-30 | $216.74 Million | $-103.15 Million | -0.476x | -80.39% |
| 2022-09-30 | $321.33 Million | $-84.78 Million | -0.264x | -50.56% |
| 2021-09-30 | $399.43 Million | $-70.00 Million | -0.175x | -1226.35% |
| 2020-09-30 | $455.58 Million | $7.09 Million | 0.016x | -89.92% |
| 2019-09-30 | $462.49 Million | $71.42 Million | 0.154x | +108.05% |
| 2018-09-30 | $393.68 Million | $29.22 Million | 0.074x | -57.47% |
| 2017-09-30 | $301.68 Million | $52.65 Million | 0.175x | +31.57% |
| 2016-09-30 | $269.94 Million | $35.81 Million | 0.133x | -59.14% |
| 2015-09-30 | $236.16 Million | $76.67 Million | 0.325x | +139.18% |
| 2014-09-30 | $148.65 Million | $20.18 Million | 0.136x | +40.76% |
| 2013-09-30 | $110.47 Million | $10.65 Million | 0.096x | -81.27% |
| 2012-09-30 | $43.93 Million | $22.62 Million | 0.515x | +382.94% |
| 2011-09-30 | $-131.96 Million | $24.02 Million | -0.182x | -- |
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more